Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...
Key points A 68-year-old woman from rural Ontario arrived at her local emergency department with worsening palpitations. Her medical history included breast cancer treated with surgical resection and ...
Cardiologists often struggle to assess heart attack risk. New startups using AI could help.
Novo Nordisk’s oral semaglutide Rybelsus reduced the risk for major adverse cardiovascular events by 14% in people with type ...
Ken’s search for answers brought him to nearly a dozen doctors. After months of tests, he was finally diagnosed with a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback